NNVC Stock Overview
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NanoViricides, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.10 |
| 52 Week High | US$2.00 |
| 52 Week Low | US$1.00 |
| Beta | 0.71 |
| 1 Month Change | -2.65% |
| 3 Month Change | 2.80% |
| 1 Year Change | -17.29% |
| 3 Year Change | -73.49% |
| 5 Year Change | -78.00% |
| Change since IPO | -92.86% |
Recent News & Updates
Shareholder Returns
| NNVC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 1.0% |
| 1Y | -17.3% | 0.9% | 21.9% |
Return vs Industry: NNVC underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: NNVC underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| NNVC volatility | |
|---|---|
| NNVC Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NNVC's share price has been volatile over the past 3 months.
Volatility Over Time: NNVC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 7 | Anil Diwan | www.nanoviricides.com |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company’s product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
NanoViricides, Inc. Fundamentals Summary
| NNVC fundamental statistics | |
|---|---|
| Market cap | US$12.96m |
| Earnings (TTM) | -US$9.36m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs NNVC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNVC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.36m |
| Earnings | -US$9.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NNVC perform over the long term?
See historical performance and comparison